House Bill Would Expand Medicare Coverage for Obesity Drugs and Counseling
This bill is currently in the House committee stage and has not moved forward since June 2025. It is considered stalled because no action has been taken by the committees for over 12 months. The House committees must review the bill before it can proceed to any further steps.
No action since June 2025
This bill’s path across every version that has carried it.
How this policy affects specific groups of people
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Bipartisan legislation like the Treat and Reduce Obesity Act seeks to allow Medicare coverage for FDA-approved obesity medications and visits with specialists, potentially saving the system billions by reducing chronic disease complications.
CMS announced the BALANCE program, a voluntary model allowing Medicare beneficiaries to access GLP-1 medications for $50 a month, addressing the same access gaps targeted by the Treat and Reduce Obesity Act of 2025.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Treat and Reduce Obesity Act of 2025
Analysis generated by AI. Always verify with official sources.